Please try another search
For the nine months ended 31 December 2019, GlaxoSmithKline Consumer Healthcare Ltd revenues increased 6% to RS36.98B. Net income before extraordinary items increased 34% to RS9.34B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Other Income increase of 4% to RS3.21B (income), Others decrease of 1% to RS7.22B (expense).
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Total Revenue | 11588.6 | 13450.9 | 11943.2 | 12860.55 |
Gross Profit | 8047.5 | 9505.4 | 8354.9 | 8997.77 |
Operating Income | 2529.1 | 3754.8 | 2607.8 | 3035.55 |
Net Income | 2766.3 | 3453.1 | 2480.8 | 2858.14 |
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Total Assets | 61425.7 | 60680.89 | ||
Total Liabilities | 19808.1 | 19733.75 | ||
Total Equity | 41617.6 | 40947.14 |
Period Ending: | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 |
---|---|---|---|---|
Period Length: | 0 Months | 6 Months | 0 Months | 0 Months |
Cash From Operating Activities | 5137.9 | 6710.68 | ||
Cash From Investing Activities | -1154.6 | -3350.57 | ||
Cash From Financing Activities | -5460.6 | -3767.95 | ||
Net Change in Cash | -1477.3 | -407.85 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review